Abstract
A randomized controlled comparative study of oral medroxyprogesterone acetate (MPA) 1,200 mg (arm I) and 600 mg (arm II) was conducted in 80 patients with advanced or recurrent breast cancer. There were no significant differences between arm I and arm II in terms of response rate, duration of response and survival, or in terms of incidence and severity of adverse reactions. The lowest serum MPA concentration in responders tended to be higher than that in nonresponders. In the cohort of this study, the lowest concentration in partial response was 17.4 ng/ml, suggesting that this level may be the required minimum serum concentration.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Agents, Hormonal / administration & dosage
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Agents, Hormonal / blood
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Breast Neoplasms / blood
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Drug Administration Schedule
-
Female
-
Humans
-
Hydrocortisone / blood
-
Medroxyprogesterone Acetate / administration & dosage
-
Medroxyprogesterone Acetate / adverse effects
-
Medroxyprogesterone Acetate / blood
-
Medroxyprogesterone Acetate / therapeutic use*
-
Middle Aged
-
Neoplasm Recurrence, Local / blood
-
Neoplasm Recurrence, Local / drug therapy*
-
Survival Analysis
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Hormonal
-
Medroxyprogesterone Acetate
-
Hydrocortisone